Checking immunotoxicity risks of checkpoint blockade

Nat Cancer. 2023 Jun;4(6):779-780. doi: 10.1038/s43018-023-00561-8.

Authors

Dietmar Rieder¹, Zlatko Trajanoski²

Affiliations

¹ Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
² Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria. zlatko.trajanoski@i-med.ac.at.

PMID: 37308677
DOI: 10.1038/s43018-023-00561-8

No abstract available

MeSH terms

Antibodies, Monoclonal*
CTLA-4 Antigen

Substances

Antibodies, Monoclonal
CTLA-4 Antigen